跳至主要内容
临床试验/NCT01106781
NCT01106781已完成不适用

A Non-interventional Survey on the Epidermal Growth Factor Receptor (EGFR) Mutation Status in Completely Resected Chinese Non-Small Cell Lung Cancer (NSCLC) Patients With Adenocarcinoma Histology

AstraZeneca1 个研究点 分布在 1 个国家目标入组 591 人开始时间: 2010年8月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
AstraZeneca
入组人数
591
试验地点
1
主要终点
type and prevalence of EGFR mutation

研究概览

简要总结

This is a descriptive observational study. The primary objective is to explore the EGFR gene mutation status in early stage NSCLC with adenocarcinoma histology after complete resection. The patients should be histological confirmed adenocarcinoma of the lung, have received complete resection and tested for EGFR mutation in regular medical practice.

研究设计

研究类型
Observational
观察模型
Case Only
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Histological diagnosed as adenocarcinoma type of non-small cell lung cancer
  • Have completed lung cancer operation
  • The tumour EGFR gene mutation status test was performed as regular medical practice

排除标准

  • Patients who disagree to participate this study

结局指标

主要结局

type and prevalence of EGFR mutation

时间窗: up to 3 months

次要结局

  • Operation type and adjuvant treatment type(up to 3 months)
  • Disease Free Survival rate(up to 3 months)

研究者

发起方
AstraZeneca
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验